Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEIZALAM vs ONFI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.
Status epilepticus,Acute repetitive seizures,Seizure clusters
Treatment of seizures associated with Lennox-Gastaut syndrome,Adjunctive therapy for other seizure types
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
The terminal elimination half-life of clobazam is 36–42 hours. The active metabolite N-desmethylclobazam has a half-life of 71–82 hours. The long half-life permits once-daily dosing but also leads to slow accumulation; steady-state is achieved after 2–3 weeks.
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Hepatic via CYP3A4 and CYP2C19; primary metabolite N-desmethylclobazam is active.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
Clobazam (ONFI) undergoes extensive hepatic metabolism. Approximately 82% of the dose is eliminated in urine (as unchanged drug and metabolites) and about 11% in feces. Unchanged clobazam accounts for <1% of urinary excretion. The major metabolite, N-desmethylclobazam, is excreted primarily renally.
Approximately 98% bound to albumin.
Clobazam is approximately 80–90% bound to plasma proteins, primarily albumin.
1.0–1.5 L/kg; reflects extensive tissue distribution.
The apparent volume of distribution is approximately 100 L (range 77–120 L), or roughly 1.4 L/kg. This large Vd indicates extensive tissue distribution and accumulation in fatty tissues.
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
Oral bioavailability is nearly complete (>90%). Clobazam is well absorbed after oral administration with only minor first-pass metabolism.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
No specific GFR-based dose adjustments; use with caution in severe impairment (Cr Cl < 30 m L/min) due to potential for increased sedation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Mild to moderate (Child-Pugh A/B): Initial 5 mg orally twice daily; may increase by 5 mg/day after 1 week to maximum 20 mg/day. Severe (Child-Pugh C): Not recommended.
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
Clobazam (ONFI) for seizures: Age 2 to <6 years, body weight ≥12.5 kg: Initial 5 mg orally once daily; titrate to maintenance 5 mg twice daily. Age ≥6 years: Weight ≤30 kg: Initial 5 mg once daily; titrate to 5 mg twice daily (max 20 mg/day). Weight >30 kg: same as adult dosing. Administer with food.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
Elderly (≥65 years): Initial 5 mg orally twice daily; increase slowly to lowest effective maintenance due to increased sensitivity and risk of falls. Avoid doses above 20 mg/day unless clearly necessary.
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients for whom alternative treatment options are inadequate.
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Risk of respiratory depression, especially with opioids,Sedation and somnolence,Risk of abuse and dependence,Withdrawal seizures on abrupt discontinuation,Increased risk of suicidal thoughts or behavior
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
Hypersensitivity to clobazam or any component of formulation,Severe hepatic impairment
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
Avoid grapefruit and grapefruit juice as they may increase clobazam levels. No other significant food interactions are known. CNS depressant effects may be potentiated by alcohol.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia, poor feeding, respiratory depression, and hypothermia; consistent exposure may cause floppy infant syndrome. Late pregnancy exposure linked to neonatal benzodiazepine withdrawal syndrome.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
Clobazam is excreted into breast milk; M/P ratio approximately 0.5-0.6. Accumulation possible in neonates; monitor for sedation, poor feeding, apnea. Avoid if infant has impaired hepatic function or low birth weight. American Academy of Pediatrics recommends caution; use lowest effective maternal dose.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
Increased clearance during pregnancy (CYP3A4 induction); plasma concentrations may decrease by 30-50% in third trimester. Dose adjustments often required: monitor therapeutic response and consider dose increase by 50-100% in late pregnancy; postpartum reduce to prepregnancy dose over 1-2 weeks to avoid toxicity.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
ONFI (clobazam) is a benzodiazepine indicated for seizures associated with Lennox-Gastaut syndrome. Titrate slowly to minimize sedation. Monitor for withdrawal symptoms upon discontinuation; taper over several weeks. Not recommended for use in patients with severe hepatic impairment (Child-Pugh C). For patients on other CNS depressants, consider dose reduction. Clobazam's active metabolite, N-desmethylclobazam, has a long half-life (36-46 hours) and can accumulate, especially in poor CYP2C19 metabolizers. In such patients, consider lower doses and monitor for excessive sedation.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
Take ONFI exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Avoid alcohol and other sedatives while taking this medication due to increased risk of drowsiness and respiratory depression.,Report any unusual mood changes, depression, or suicidal thoughts to your healthcare provider.,Do not drive or operate heavy machinery until you know how ONFI affects you, as it can cause dizziness and drowsiness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using ONFI.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SEIZALAM vs ONFI, answered by our medical review team.
SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. ONFI is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SEIZALAM and ONFI depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. The standard adult dose of ONFI is: Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SEIZALAM and ONFI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. ONFI is classified as Category C. Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.